Advertisement

Topics

Companies Related to "Immunotherapeutics Immune Checkpoint Inhibitor Effi 24th Molecular 2017" [Most Relevant Company Matches] - Page: 4 RSS

11:11 EDT 24th March 2019 | BioPortfolio

Here are the most relevant search results for "Immunotherapeutics Immune Checkpoint Inhibitor Effi 24th Molecular 2017" found in our extensive corporate database of over 50,000 company records.

Showing "Immunotherapeutics Immune Checkpoint Inhibitor Effi 24th Molecular 2017" Companies 76–100 of 1,900+

Probably Relevant

Quentis Therapeutics

Quentis Therapeutics is a preclinical stage biotechnology company that is translating novel biology into new therapeutic approaches to help more cancer patients benefit from immunotherapy. Based on our deep expertise in endoplasmic reticulum (ER) stress biology and the tumor microenvironment, we are pioneering first-in-class ER stress response modulators t...


Biothera Pharmaceuticals, Inc.

Biothera is a privately held biotechnology company developing Imprime PGG, a clinical stage immunotherapy drug that modulates key immune cells to orchestrate a coordinated immune response to cancer that involves both the innate and adaptive immune system. Proof of concept has been established from single-arm and randomized phase 2 studies in non-small cell...

Lorantis

Lorantis is discovering and developing breakthrough products for the selective treatment of immunological and inflammatory diseases based on immune regulation: the induction of antigen-specific tolerance. Current therapies for immunological and inflammatory diseases either relieve only the symptoms or induce non-specific suppression of the immune system. This can lead to severe infection and drug-...


CTMM

CTMM (Center for Translational Molecular Medicine) is a Netherlands-based public-private partnership dedicated to the development of technologies in molecular medicine that enable early diagnosis and personalised treatment for oncology, cardiovascular, neurodegenerative and infectious/auto-immune disease - the four main areas of disease causing mortality and diminished quality of life in the w...

Bayhill Therapeutics Inc

Bayhill Thereapeutics is a clinical-stage biopharmaceutical company at the forefront of developing novel and targeted treatment candidates for autoimmune diseases. Leveraging its proprietary therapeutic BHT-DNA™ platform, the Company’s product candidates have been designed to restore the immune system to its normal state, known as “tolerance,”...

Iterion Therapeutics

Iterion Therapeutics is a venture-backed, clinical stage biotechnology company developing novel targeted cancer therapeutics. The company’s lead product, Tegavivint, is a potent and selective inhibitor of the Wnt/b-catenin signaling pathway, implicated in cell proliferation, differentiation, immune evasion and stem cell renewal. Tegavivint demonstrate...

Akebia Therapeutics, Inc.

Akebia Therapeutics is a discovery and development company focused on anemia and vascular disorders. Akebia’s lead program, AKB-6548, an orally bioavailable HIF-prolyl hydroxylase (HIF-PH) inhibitor for patients with anemia, is in phase 2 clinical trials. AKB-6548 potentially promises to be a safer, less expensive, orally dosed pharmaceutical to stimu...

Gliknik Inc.

Founded in 2007, Gliknik is a biopharmaceuticals company creating new therapies for patients with cancer and immune disorders. Gliknik expertise is in modulation of the immune system to fight disease. Gliknik was named a 2009 Maryland Incubator Company of the Year. Learn more at www.gliknik.com.

Ardea Biosciences, Inc.

Ardea Biosciences, Inc., of San Diego, California, is a biotechnology company focused on the development of small-molecule therapeutics for the treatment of gout, cancer and human immunodeficiency virus (HIV). RDEA594, our lead product candidate for the treatment of hyperuricemia and gout, is a selective URAT1 transporter inhibitor in Phase 2 clinical development. Our next-generation URAT1 inhib...

OLIVE OIL KANSAI 2017

Centocor, Inc.

The immune system has many secrets…but not for long. Centocor is fundamentally changing the treatment of immune-related disease. The immune system is the new frontier—and the way we view it is unique. Through the visionary science of biotechnology, we pioneer breakthrough biomedicines that transform patients’ lives

InterMune, Inc.

InterMune is a biotechnology company focused on the research, development and commercialization of innovative therapies in pulmonology and hepatology. InterMune has an R&D portfolio addressing idiopathic pulmonary fibrosis (IPF) and hepatitis C virus (HCV) infections. The pulmonology portfolio includes pirfenidone, for which InterMune has completed the Phase 3 CAPACITY program in patients with I...

Caerus Discovery LLC

Caerus Discovery LLC is a privately owned company based on the Prince William Campus of George Mason University in Manassas, VA. Caerus is focused on the discovery of new molecular targets for cancer, autoimmune, inflammatory and infectious diseases. Caerus plans to further develop and optimize novel discovery paradigms employing immune tolerance induction...

Coridon Pty Ltd

Coridon is a privately held company headquartered in Brisbane Australia. The company was founded in 2000 for the purpose of developing DNA therapies for the prevention and treatment of viral infections such as Herpesvirus and Hepatitis C and therapeutic vaccines for the treatment of cancer.Our mission is to develop new DNA immunotherapies that achieve effective immune responses. These effective im...

Quentis Therapeutics Inc.

Quentis Therapeutics is a preclinical stage biotechnology company that is pursuing first-in-class endoplasmic reticulum (ER) stress response-targeted therapies to address serious diseases such as cancer. Based on our deep expertise in ER stress biology and the tumor microenvironment, we are pioneering the use of ER stress response modulators to boost the i...

Blade Therapeutics

Blade Therapeutics is a private biopharmaceutical company advancing novel anti-fibrotic therapies to meet important patient needs. Blade has assembled a critical mass of fibrosis expertise and a top-tier leadership team and world-class network of advisors with unparalleled experience in anti-fibrotic drug R&D. Blade ’s lead program is a small molecule...

CANVAC COORDINATING CENTRE

CANVAC, the Canadian Network for Vaccines and Immunotherapeutics, is a unique network of almost 80 of the most highly recognised Canadian scientists specialising in the fields of immunology, virology, and molecular biology. CANVAC researchers, who are faculty members selected from 21 Canadian universities and research institutes are working in collaboration with: 23 corporate partners from the bio...

Immunitor Corporation Co., Ltd

Immunitor Corporation Co., Ltd., is the first private biotech company formed in Thailand Technology developed by Immunitor allows to formulate any desired immunogen or antigen as an oral tablet.Such antigens are formulated into an ordinary appearing pill in such a way that they can withstand the digestive degradation in the stomach but are capable to trigger immune response once pr...

Natural Molecular Testing Corp.

Natural Molecular Testing Corporation (NMTC) is a privately-owned, high-complexity molecular testing facility. NMTC provides genetic testing services and resources for our clinical partners to assist them in better caring for their patients by advancing patient care through the latest breakthroughs in genomic technology.

Immune Targeting Systems

Immune Targeting Systems is a London based biotech company developing vaccines for mutating viruses based on its broadly applicable next generation DepoVaccine and High Density (HD) Antigen identification technology platforms.

Kowa Company, Ltd.

Kowa Company, Ltd. (Headquarters: Nagoya, Japan , President & CEO: Yoshihiro Miwa, "Kowa") is a privately held multinational company headquartered in Nagoya, Japan. Established in 1894, Kowa is actively engaged in various manufacturing and commercial activities in the fields of pharmaceutical, life science, information technology, textiles, machinery and v...

Susavion Biosciences, Inc.

The founders of Susavion Biosciences, Dr. Laura L. Eggink and Dr. J. Kenneth Hoober, developed a platform of novel peptide drugs, which have the potential to provide a breakthrough approach for treating diseases around the world. Susavion is well-positioned to capitalize on the emerging opportunities in immunotherapeutics for todays’s most challenging...

Center of Molecular Immunology

The Center of Molecular Immunology (CIM) is a Cuban Biotechnological Institution devoted to basic research, product development and production of mammalian cell culture products such as monoclonal antibodies and recombinant proteins. CIM’s research goals focus on cancer and immune system related disorders. The 15 000 m2 two floor facility has a cGMP production area designed for maximum prod...

TBWA Worldwide

TBWA Worldwide (www.tbwa.com) creates Disruptive ideas for global clients, including ABSOLUT, adidas, Apple, Beiersdorf, GSK, Henkel, Infiniti, Mars, McDonald's, Michelin, Nissan, Pernod Ricard, Samsonite, Standard Chartered Bank, Singapore Airlines, Sony PlayStation and Visa. TBWA is one of the fastest-growing networks in the Top-Ten worldwide advertising agencies, and was named 2008 Global Agenc...

Alexion Pharmaceuticals Incorporated

Alexion is a global biopharmaceutical company that combines groundbreaking science with a steadfast commitment to meeting the needs of patients living with severe, life-threatening and often ultra-rare diseases. Alexion scientists are among the first in the world to unlock the therapeutic potential of inhibiting terminal complement, a group of proteins that play an important role in the body's imm...


More From BioPortfolio on "Immunotherapeutics Immune Checkpoint Inhibitor Effi 24th Molecular 2017"

Advertisement
Quick Search
Advertisement
Advertisement

 

Corporate Database Quicklinks